{"entity":{"id":"nct07011576","kind":"trial","name":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","aka":["FRUITFUL"],"tldr":"A phase 2 trial of fruquintinib and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by SCRI Development Innovations, LLC, now recruiting.","summary":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) is a phase 2, interventional study registered as NCT07011576 by SCRI Development Innovations, LLC, with a registry enrolment figure of 60 participants, started 2025-09-29 and due to reach its primary completion in 2027-01. Interventions recorded: fruquintinib; FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin). Conditions listed: Colon Cancer; Rectal Cancer; Colorectal Cancer; Colorectal Cancer (CRC). Primary outcome: Progression-Free Survival (PFS) rate at 6 months. Colorectal eligibility wording from the registry: \"* Confirmed mCRC ; histologically documented adenocarcinoma of the colon or rectum with at least one measurable lesion according to RECIST v1\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07011576","url":"https://clinicaltrials.gov/study/NCT07011576"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","kinase-inhibitors","topoisomerase-inhibitors"],"targets":[],"drugs":["fruquintinib","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07011576","phase":"2","setting":"A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","sponsor":"SCRI Development Innovations, LLC","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07011576/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}